- Home
- CTNM
as of 03-04-2026 3:40pm EST
$14.73
+$0.63
+4.47%
Stocks Nasdaq
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 575.3M | IPO Year: | 2024 |
| Target Price: | $18.60 | AVG Volume (30 days): | 176.0K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | -2825.00 |
| 52 Week Low/High: | $3.35 - $16.33 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -6.44 | Index: | N/A |
| Free Cash Flow: | -33359000.0 | FCF Growth: | N/A |
AI-Powered CTNM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 80.88%
80.88%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Contineum Therapeutics Inc. (CTNM)
Lorrain Daniel S.
Sell
Chief Scientific Officer
CTNM Mar 2, 2026
Avg Cost/Share
$15.01
Shares
4,170
Total Value
$62,585.03
Owned After
151,882
SEC Form 4
Watkins Tim
Sell
CMO & Head of Development
CTNM Mar 2, 2026
Avg Cost/Share
$15.02
Shares
3,611
Total Value
$54,220.25
Owned After
0
SEC Form 4
Lorrain Daniel S.
Sell
Chief Scientific Officer
CTNM Feb 25, 2026
Avg Cost/Share
$16.01
Shares
3,824
Total Value
$61,227.98
Owned After
151,882
SEC Form 4
Stengone Carmine N.
Sell
CEO and President
CTNM Feb 25, 2026
Avg Cost/Share
$16.02
Shares
2,700
Total Value
$43,241.85
Owned After
14,954
SEC Form 4
Lorrain Daniel S.
Sell
Chief Scientific Officer
CTNM Feb 24, 2026
Avg Cost/Share
$16.03
Shares
4,300
Total Value
$68,935.88
Owned After
151,882
SEC Form 4
Stengone Carmine N.
Sell
CEO and President
CTNM Feb 24, 2026
Avg Cost/Share
$16.02
Shares
4,400
Total Value
$70,485.80
Owned After
14,954
SEC Form 4
Lorrain Daniel S.
Sell
Chief Scientific Officer
CTNM Feb 11, 2026
Avg Cost/Share
$16.00
Shares
400
Total Value
$6,400.00
Owned After
151,882
SEC Form 4
Stengone Carmine N.
Sell
CEO and President
CTNM Feb 11, 2026
Avg Cost/Share
$16.00
Shares
400
Total Value
$6,400.00
Owned After
14,954
SEC Form 4
Lorrain Daniel S.
Sell
Chief Scientific Officer
CTNM Feb 3, 2026
Avg Cost/Share
$15.03
Shares
4,170
Total Value
$62,305.47
Owned After
151,882
Watkins Tim
Sell
CMO & Head of Development
CTNM Jan 28, 2026
Avg Cost/Share
$14.29
Shares
3,611
Total Value
$51,188.25
Owned After
0
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | CTNM | Chief Scientific Officer | Mar 2, 2026 | Sell | $15.01 | 4,170 | $62,585.03 | 151,882 | |
| Watkins Tim | CTNM | CMO & Head of Development | Mar 2, 2026 | Sell | $15.02 | 3,611 | $54,220.25 | 0 | |
| Lorrain Daniel S. | CTNM | Chief Scientific Officer | Feb 25, 2026 | Sell | $16.01 | 3,824 | $61,227.98 | 151,882 | |
| Stengone Carmine N. | CTNM | CEO and President | Feb 25, 2026 | Sell | $16.02 | 2,700 | $43,241.85 | 14,954 | |
| Lorrain Daniel S. | CTNM | Chief Scientific Officer | Feb 24, 2026 | Sell | $16.03 | 4,300 | $68,935.88 | 151,882 | |
| Stengone Carmine N. | CTNM | CEO and President | Feb 24, 2026 | Sell | $16.02 | 4,400 | $70,485.80 | 14,954 | |
| Lorrain Daniel S. | CTNM | Chief Scientific Officer | Feb 11, 2026 | Sell | $16.00 | 400 | $6,400.00 | 151,882 | |
| Stengone Carmine N. | CTNM | CEO and President | Feb 11, 2026 | Sell | $16.00 | 400 | $6,400.00 | 14,954 | |
| Lorrain Daniel S. | CTNM | Chief Scientific Officer | Feb 3, 2026 | Sell | $15.03 | 4,170 | $62,305.47 | 151,882 | |
| Watkins Tim | CTNM | CMO & Head of Development | Jan 28, 2026 | Sell | $14.29 | 3,611 | $51,188.25 | 0 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K BUY Oct 30, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K BUYOct 30, 2025 · 100% conf.
AI Prediction BUY
1D
+5.73%
$11.14
5D
+9.09%
$11.50
20D
+18.14%
$12.45
Price: $10.54 Prob +5D: 100% AUC: 1.000
0001437749-25-032422
ctnm20251015_8k.htm
false 0001855175
0001855175
2025-10-30 2025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2025
Contineum Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-42001
27-1467257
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
3565 General Atomics Court, Suite 200
San Diego, California
92121
(Address of principal executive offices)
(Zip Code)
(858) 333-5280
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share
CTNM
The Nasdaq Global Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 30, 2025, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated October 30, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 30, 2025
Contineum Therapeutics, Inc.
By:
/s/ Peter Slover
Peter Slover
Chief Financial Officer
Principal Financial Officer and Principal Accounting Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0001437749-25-024849
ctnm20250616_8k.htm
false 0001855175
0001855175
2025-08-05 2025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2025
Contineum Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-42001
27-1467257
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
3565 General Atomics Court, Suite 200
San Diego, California
92121
(Address of principal executive offices)
(Zip Code)
(858) 333-5280
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share
CTNM
The Nasdaq Global Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated August 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 5, 2025
Contineum Therapeutics, Inc.
By:
/s/ Peter Slover
Peter Slover
Chief Financial Officer
Principal Financial Officer and Principal Accounting Officer
2025 Q1 Q1 2025 Earnings
8-K May 14, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 14, 2025
0001437749-25-016877
cont20250321_8k.htm
false 0001855175
0001855175
2025-05-14 2025-05-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2025
Contineum Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-42001
27-1467257
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
3565 General Atomics Court, Suite 200
San Diego, California
92121
(Address of principal executive offices, including zip code)
(Zip Code)
(858) 333-5280
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share
CTNM
The Nasdaq Global Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 14, 2025, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.
Item 8.01 Other Events.
On May 14, 2025, the Company filed a Shelf Registration Statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”) registering the sale of up to $300.0 million in the aggregate of the Company’s securities in one or more offerings over a three-year period.
The Company also entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (“Leerink Partners”) relating to the offer and sale of up to $75.0 million in shares of its Class A common stock, par value $0.001 per share (the “Shares”). The Registration Statement contains a prospectus covering the sale of Shares pursuant to the Agreement. The Company is not obligated to make any sales of Shares under the Agreement. Any sales under the Agreement will be made pursuant to an “at-the-market offering” in accordance with Rule 415(a)(4) under the Securities Act of 1933, as amended. The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of such Agreement, a copy of which is filed as Exhibit 1.2 to the Registration Statement and is incorporated herein by reference.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any offer, solicitation, or sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
1.1
Sales Agreement, dated May 14, 2025, by and between Contineum Therapeutics, Inc. and Leerink Partners (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 filed with the SEC on May 14, 2025).
99.1
Press release dated May 14, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant
Latest Contineum Therapeutics Inc. News
CTNM Breaking Stock News: Dive into CTNM Ticker-Specific Updates for Smart Investing
Compare CTNM vs Leading Stocks
See how CTNM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CTNM Contineum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.